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Introduction
Green tea, prepared from the leaves of Camillia sinesis, is a popular beverage that is purported to have a number of beneficial health effects including antithrombotic, antiinflammatory and anticancer activities (Higdon and Frei, 2003; Wolfram, 2007; Clement, 2009 ). Green tea is rich in polyphenolic compounds known as catechins, and it is these catechins that are believed to be responsible for the physiological activity of green tea and its extracts. The major catechin found in green tea is epigallocatechin-3-gallate (EGCG, Figure 1 ) which constitutes approximately 65% of the total catechins found in green tea (Balentine et al., 1997) . On average, brewed green tea provides 78 mg of EGCG per cup (US Department of Agriculture). EGCG is also available for consumption in the form of concentrated extracts of green tea sold as over-the-counter nutritional supplements containing up to 200-400 mg of ECGC per dose. These concentrated preparations are used both as dietary supplements as well as in controlled human clinical trials (see www.clinicaltrials.gov).
A number of studies have examined the effects of EGCG on various biochemical pathways (Beltz et al., 2006 : Milacic et al., 2008 Tachibana, 2009 ). However, relatively few studies have been conducted to assess its effects on voltage-dependent ion channels.
In one study carried out in hippocampal neurons it was shown that voltage-dependent Na + channels were only weakly inhibited by EGCG with an IC 50 value of approximately 200 µM (Deng et al., 2008) . In contrast, another study in dorsal root ganglion cells found that the voltage-dependent Na + current in this preparation was much more sensitive to EGCG, being inhibited by sub-micromolar concentrations (Kim et al., 2009) . In vascular smooth muscle cells, EGCG produced a complex biphasic effect (both activation and This article has not been copyedited and formatted. The final version may differ from this version.
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jpet.aspetjournals.org Downloaded from JPET #169391 5 inhibition) on the L-type Ca ++ channel (Campos-Toimil and Orallo, 2007) while Ca ++ channel currents in bovine chromaffin cells were unaffected by the compound (Pan et al., 2002) . Finally, the human ether-a-go-go-related gene (HERG) cardiac K + channel was shown to be inhibited by EGCG with an IC 50 value of 6 µM (Kelemen et al., 2007) .
These studies suggest that voltage-dependent ion channels could, at least in some tissues, be pharmacological targets for the effects of EGCG. Nevertheless, with the exception of the study on HERG, little if anything is know about the effects of EGCG on voltagedependent ion channels in the heart. For this reason we decided to examine the activity of EGCG on the electrocardiogram (ECG) waveform recorded from Langendorff-perfused guinea pig hearts. Following this we tested the effects of EGCG on individual voltagedependent ion channels found in the myocardium.
This article has not been copyedited and formatted. The final version may differ from this version. Langendorff Heart Preparation. The method used has been described previously (Cheng et al., 2006) . Male guinea pigs, weighing 830 to 850g, were used for this investigation. Under isofluorane anesthesia (4.5%), the heart was removed rapidly from the animal and was cannulated for perfusion of the coronary artery (70 cm H 2 O)
with Locke solution according to the Langendorff method. The heart was bathed in a 100 ml tissue chamber containing Locke's solution that was continuously bubbled with O 2 at 35 o C and had the following composition (in mM): NaCl, 153.6, KCl, 5.6, CaCl 2 , 2.0, NaHCO 3 , 6.0, dextrose, 11.1, Sodium pyruvate, 2.0, and Na 2 EDTA, 0.05. In vitro equivalent lead II ECG waveforms were recorded via volume-conducted current using a ring electrode assembly (Cheng et al., 2006) , and an ECG data acquisition system (Buxco Electronics, Inc., Wilmington, NC).
The heart was paced by using a pair of needle electrodes positioned in the right atrium near the SA node at 1 msec pulse duration, approximately 20% above threshold voltage at a rate of 210 beats/min and was allowed to equilibrate for 2 hours before drug testing. The heart was perfused with vehicle (Locke's solution), and then with 3, 10, and 30 µM of EGCG, for 20 minutes at each concentration. EGCG (30 µM) was also tested in spontaneously beating guinea pig hearts and its effects on ECG parameters were recorded for 20 minutes.
This article has not been copyedited and formatted. The final version may differ from this version. bovine serum in an atmosphere of 95% air/5% carbon dioxide. The cDNA encoding SCN5A, the human cardiac Na + channel (Nav1.5), was stably transfected into human embryonic kidney cells (American Type Culture Collection) as described previously (Kuryshev et al., 2000) . Single ventricular myocytes were isolated from guinea pigs and used to record Ca ++ channel currents. Single ventricular myocytes were isolated from guinea pigs using a method modified from that described by Salata et al. (1995) . In brief, Patch-Clamp Recording. Unless stated otherwise, all ionic currents were recorded at 35 ± 1°C using the whole-cell configuration of the patch-clamp technique (Hamill et al., 1981) . Cells were exposed to EGCG until any observed effect on the currents came to equilibrium, generally about 3-4 minutes. Electrodes (1-3 MΩ resistance) were made from TW150F glass capillary tubes (WPI, Sarasota, FL). For HERG and Kv4.3 K + channel recordings, electrodes were filled with the following solution: 120 mM potassium aspartate, 20 mM KCl, 4 mM di-sodium adenosine triphosphate, 5 mM HEPES, 1 mM MgCl 2 , pH 7.2 with KOH, while for KvLQT1/minK channel recordings, electrodes were filled with internal solution containing 120 mM potassium aspartate, 20 mM KCl, 4 mM Na 2 ATP, 5 mM HEPES; 1 mM MgCl 2 , 14 mM sodium phosphocreatine, 0.3 mM sodium GTP, 50 units/ml creatine phosphokinase (pH 7.2 with KOH). The external solution contained: 130 mM NaCl, 4 mM KCl, 2.8 mM sodium acetate, 1 mM MgCl 2 , 10 mM HEPES, 10 mM glucose, 1 mM CaCl 2 , pH 7.4
This article has not been copyedited and formatted. The final version may differ from this version. with NaOH. The internal and external solutions for Na + and Ca ++ channels recordings have been described previously (Kang et al., 2004) . All ionic currents were recorded using an Axopatch 200B amplifier (Danaher Corporation, Sunnyvale, CA) and were analyzed using the Clampfit program within the pCLAMP suite of software (Danaher Corporation). IC 50 values and 95% confidence limits (95% C.L.) were obtained by nonlinear least squares fit of the data (GraphPad Software, Inc., San Diego, CA). All other data are expressed as the mean ± S.E.M.
Chemicals. EGCG was purchased from Sigma Aldrich (St Louis, MO) and was dissolved directly into the external solutions. EGCG was prepared fresh from powder just prior to all experiments since prolonged storage or freezing/thawing stock solutions appeared to cause degradation (e.g. brown discoloration of solutions). All other reagents were obtained from commercial sources.
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Results
To establish whether EGCG has effects on cardiac electrophysiology, we first examined its activity on ECG waveforms measured in guinea pig hearts using the Langendorff method. At concentrations of 3 and 10 µM, no statistically significant changes were apparent in any of the ECG values measured (PR, QRS, QT and Tp -Te intervals, Table 1 ). At a concentration of 30 µM, the ECG waveform was clearly altered and all the measured parameters were significantly different from their corresponding control values. The most obvious difference noted in the ECG was a change in the ST-Twave segment (Figure 2 ). This was characterized by an elevation in the area that approximates the J point, and a merging of the ST segment with the upslope of the Twave (observed in 3/5 hearts). We also noted a slowing of the terminal phase of the Twave (observed in all hearts tested). Since it was consistently seen in all hearts tested, we quantitated the effects of EGCG on the terminal phase of the T-wave by measuring the Tp-Te interval. The Tp-Te value measured 15 ± 3 ms under control conditions and 39 ± 10 ms following the addition of 30 µM EGCG (p < 0.01, ANOVA). Along with the alteration in the ST-T-wave segment, we also observed that PR and QRS interval durations were prolonged, and that the QT interval was slightly shortened (Table 1) . In addition to this data, obtained in paced hearts, we also examined the effects of 30 µM EGCG in spontaneously beating hearts, mainly to assess its effects on heart rate. EGCG at 30 µM had no effect on heart rate (177 ± 6 bpm in control versus 175 ± 7 bpm after EGCG; p>0.05 ANOVA). All other ECG parameters were changed in a quantitatively similar manner as described for the paced heart. This includes altered ST-T-waves as described for the paced hearts (observed in 4/5 hearts, Figure 3 ) as well as all other This article has not been copyedited and formatted. The final version may differ from this version. (Table 2) . Although notched P-waves were observed in all hearts treated with EGCG Figure 3 ), they were also present in 3/5 hearts prior to exposure to the drug.
We next set about to examine what effects EGCG had on some of the major voltage-dependent ion channels found in the myocardium. Figure 4 illustrates the activity of EGCG on HERG, the K + channel that underlies the rapid delayed rectifier current, I Kr , in the heart (Sanguinetti et al., 1995) . Chinese hamster ovary cells stably expressing HERG were held at -90 mV, depolarized to +10 mV for 300-ms then repolarized via a -0.5 V/s ramp back to -90 mV (stimulation frequency, 0.2 Hz). Peak outward currents during the repolarizing ramps were recorded in the absence and presence of EGCG ( Figure 4A ). HERG was only weakly affected by EGCG. At a concentration of 30 µM, HERG currents were inhibited by 1.3 ± 2.4% while at 100 µM, the highest concentration tested, inhibition measured 22.7 ± 6.6% ( Figure 4B ). We also tested the effects of EGCG using a step-step protocol at room temperature identical to what we have described previously (Kang et al., 2004) . Under these experimental conditions 10 µM EGCG produced no inhibition of HERG current while 30 µM produced a modest 13 ± 5% reduction (n=5). Likewise Kv4.3, the K + channel that carries the transient outward current in the human heart (Dixon et al., 1996) , was little affected by EGCG. Kv4.3 currents were elicited by 300-ms depolarizing pulses to +10 mV from a holding potential of -90 mV at a frequency of 0.2 Hz. Maximum inhibition of Kv4.3 measured 9.8 ± 5.0%
at a concentration of 100 µM EGCG (Figure 4 , C and D). The effects of EGCG on the cloned human cardiac Na + channel, Nav1.5, are shown in Figure 7 . Currents were generated by 50 ms step depolarization to -20 mV from a holding potential of either -90 mV ( Figure 7A ) or -70 mV ( Figure 7B ) at a frequency of 0.2 Hz. Inhibition of Nav1.5 by EGCG was voltage-dependent. The IC 50 for EGCG block of Nav1.5 was 24.6 µM (17.4 to 34.7 µM, 95% C.L.) when measured from the -70 mV holding potential and >100 µM (45.7% inhibition at 100 µM) when measured at the -100 mV holding potential. We also noted a slight slowing of inactivation which was noted after exposure to 30 or 100 µM EGCG ( Figure 7A 13 KvLQT1/minK, the inhibitory effects of EGCG on Nav1.5 were not reversible upon wash out. Figure 7D illustrates the effects of EGCG on the voltage-dependence of Na + channel inactivation. Cells were held at -90 mV and conditioning prepulses (1-s duration) were applied from -130 mV to -30 mV in 10 mV increments and these were followed by a second pulse to -20 mV. Peak current in the absence and presence of EGCG were recorded during the -20 mV pulses. The currents were normalized to the first pulse obtained in the absence of EGCG (i.e. after the -130 mV prepulse) and the mid-potentials (V 0.5 ) and slopes (k) of the curves were fit to a Boltzman equation (I=Imax/[1+exp((V 0.5 -Vm)/k]). In the absence of EGCG, the V 0.5 value measured -64.7 ± 0.5 mV (n=6). In the presence of EGCG this value was significantly (p< 0.01 paired t-test) different and measured -70.6 ± 1.8 mV (n=6). The slope of the inactivation curve was not affect by EGCG measuring -4.9 in both the presence and absence of the drug. This article has not been copyedited and formatted. The final version may differ from this version. (Shanafelt et al., 2009) . After one month of therapy, trough plasma levels (obtained 12 hours after dosing) were measured and showed that some patients had EGCG plasma levels of approximately 10 µM (no electrocardiographic data was reported in this study).
The plasma half life of EGCG is about 3 hours and approximately 80% of EGCG exists in the plasma in the unbound form (Chow et al., 2001; Lee et al., 2002) . Therefore, peak free plasma levels of at least 10-30 µM, and possibly higher, are likely to be obtained, especially when daily multi-gram doses of EGCG are used. These plasma levels of EGCG may not only be encountered in controlled clinical trials, but could presumably be reached with the use, or misuse, of over-the-counter dietary supplements containing high levels of EGCG.
EGCG displayed a number of electrocardiographic effects in the Langendorff perfused heart. Although no QT prolongation was observed, there was a pronounced alteration of the ST-T-wave segment. This was characterized by a merging of the ST-segment with the upstroke of the T-wave as well as a prolongation of the Tp-Te interval. We presumed that these effects may be mediated, at least in part, by an This article has not been copyedited and formatted. The final version may differ from this version. (Kelemen et al., 2007) . Employing either nearphysiological temperatures and a sensitive step-ramp protocol (Kirsch et al., 2004) , or a step-step protocol at room temperature, we were unable to confirm these results and indeed found that EGCG was only a weak inhibitor of HERG. Likewise, Kv4.3 channel currents were little changed by concentrations of EGCG up to 100 µM. Instead, we found EGCG to be an inhibitor of KvLQT1/minK channel currents. Block of KvLQT1/minK by EGCG was consistent throughout a wide range of voltages and reached approximately 50% at a concentration of 30 µM, the same concentration where the alterations in the ST-T-wave segment were noted. Some of the electrocardiographic changes observed in this study, including merged ST-T-wave segments and broad T-waves, have been documented in patients with congenital long QT syndrome type 1 wherein I Ks is reduced due to mutations in KvLQT1 (Zhang et al., 2000) . The present data demonstrate that KvLQT1/minK is a target for inhibition by EGCG and that this interaction may underlie some of the changes observed in the ST-T-wave segment of the ECG.
Other electrocardiographic changes induced by EGCG included prolongations of the QRS-interval and the PR-interval. Since the QRS-wave is dependent upon Na + channel activity, we examined the effects of EGCG on the cloned human cardiac Na + channel Nav1.5. We found that EGCG inhibited Nav1.5 in a dose-dependent manner and that this inhibition was enhanced at more depolarized holding potentials. Furthermore, EGCG shifted the mid-potential of the Nav1.5 steady state inactivation curve to a more hyperpolarized potential. These data suggest that EGCG may preferentially interact with 16 an inactivated state of the Na + channel and that inhibition of cardiac Na + channel currents underlies the observed prolongation of the QRS-interval on the ECG. The effects of EGCG on L-type Ca ++ channel currents have been studied in vascular smooth muscle cells where a biphasic effect (initial stimulation followed by inhibition) was observed (Campos-Toimil and Orallo, 2007) . We observed no stimulatory effect on the L-type Ca ++ channel measured in guinea pig heart cells. Instead, EGCG produced a modest dosedependent inhibition of the L-type channel current that measured 21 and 37% at concentrations of 30 and 100 µM, respectively. We believe that this inhibitory effect on the L-type channel likely underlies the small prolongation in PR-interval that we observed in the Langendorff heart preparation. Furthermore, the inhibitory effects of EGCG on Na + and Ca ++ channels may serve to dampen any QT-interval prolongation that might be expected to occur from block of KvLQT1/minK. Finally, inhibition of these inward currents may lead to early repolarization and contribute to elevations in the Jpoint and ST-segment leading to what has been described as J-wave syndrome (Antzelevitch and Yan, 2010) .
In summary, this study has examined the effects of EGCG on the ECG waveform, and its effects on the main voltage-dependent ion channels found in the myocardium.
EGCG has numerous electrocardiographic effects that include changes in the ST-T-wave segment as well as widening of the QRS-and PR-intervals. These effects are likely due to blockade of several cardiac ion channels including KvLQT1/minK K + channels as well as Na + and Ca ++ channels. Although differences exist in the electrophysiology of the guinea pig heart and the human heart, the guinea pig Langendorff preparation has been widely used to accurately predict drug-induced ECG changes in humans (Cheng et al., 2006) . These dose levels may be reached in clinical trials, or through the excessive use/abuse of over-the-counter products containing high levels of EGCG.
Error bars indicate SEM (n=6).
